Mesothelioma Treatment Phase II Clinical Trial Offers Hope

"The biotechnology company MolMed, based in Italy, has announced positive results for their Phase II trial of NGR-hTNF for the treatment of malignant pleural mesothelioma. The trial consisted of 57 malignant pleural mesothelioma patients that were previously treated with chemotherapy.
According to MolMed’s Web site, NGR-hTNF is a compound based on the combination of a tumor [...]" (2009-6-15)
Read more...